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Schistosomiasis is a water-borne, parasitic disease of major public health importance.There
has been considerable effort for several decades toward the development of a vaccine
against the disease. Numerous mouse experimental studies using attenuated Schisto-
soma mansoni parasites for vaccination have been published since 1960s. However, to
date, there has been no systematic review or meta-analysis of these data. The aim of this
study is to identify measurable experimental conditions that affect the level of protection
against re-infection with S. mansoni in mice vaccinated with radiation attenuated cercariae.
Following a systematic review, a total of 755 observations were extracted from 105 articles
(published 1963–2007) meeting the searching criteria. Random effects meta-regression
models were used to identify the influential predictors. Three predictors were found to
have statistically significant effects on the level of protection from vaccination: increasing
numbers of immunizing parasites had a positive effect on fraction of protection whereas
increasing radiation dose and time to challenge infection had negative effects. Models
showed that the irradiated cercariae vaccine has the potential to achieve protection as high
as 78% with a single dose vaccination. This declines slowly over time but remains high
for at least 8 months after the last immunization. These findings provide insights into the
optimal delivery of attenuated parasite vaccination and into the nature and development of
protective vaccine induced immunity against schistosomiasis, which may inform the for-
mulation of human vaccines and the predicted duration of protection and thus frequency
of booster vaccines.
Keywords: schistosomiasis, attenuated cercariae, protective immunity, random effects meta-regression, animal
model, systematic review
INTRODUCTION
Schistosomiasis is a water-borne parasitic disease of major pub-
lic health importance. More than 4.5 million disability adjusted
life years (DALYs) are lost each year worldwide due to schisto-
some infection (1–4). Human schistosomiasis is mainly caused by
three species: Schistosoma mansoni, Schistosoma haematobium, and
Schistosoma japonicum (5). More than 90% of reported cases are
from sub-Saharan Africa where both S. mansoni and S. haema-
tobium infections are endemic (6). The vast majority of control
programs use the antihelminthic drug praziquantel for mass drug
administration. This low-cost and efficacious drug has achieved
a significant reduction in disease prevalence and infection inten-
sity in many endemic areas (7–10). However, there are multiple
reports of re-infection after chemotherapy (11–13). In addition,
praziquantel can clear only adult worms and has little or no effect
on existing eggs and immature worms (14). This means that there
is need for additional complementary interventions, one of which
is vaccination.
Slowly developing acquired immunity plays a crucial role in
the reduction of infection prevalence and intensity in older age
groups in endemic areas (15, 16). This suggests that exposure
to schistosome antigens can promote protective immunity in
humans; however, to date, there is no licensed schistosome
vaccine (17, 18). Currently, the leading vaccine candidate is
the 28 kDa S. haematobium GST (Sh28GST, Brand name: Bil-
hvax), which is now in phase 3 clinical trials (19–21). Along-
side recombinant antigen vaccine studies, the attenuated live
cercariae vaccine has been studied extensively in mouse mod-
els (22, 23). Properly prepared attenuated cercariae live long
enough to invade the host skin and stimulate protective acquired
immunity against subsequent challenge infection but die in the
host’s body before they mature into adult worms (24). Atten-
uated schistosome cercariae vaccination experiments in animals
use cercariae, which are weakened by ionizing radiation (X-ray
or gamma ray), ultraviolet, heat, or chemical treatment. Host
animals are immunized with attenuated parasites either once
or several times before challenge infection with non-attenuated
pathogenic cercariae. A certain number of days after the chal-
lenge infection, immunized animals and control animals are per-
fused to quantify the level of protection due to immunization
by comparing the number of adult worms recovered from both
groups.
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A large number of mouse experimental studies using attenu-
ated S. mansoni cercariae for vaccination have been published since
1960s (25); however, such studies have never been systematically
analyzed. The aim of this study was to conduct a meta-analysis
to identify measurable experimental conditions (predictors) that
affect the level of protection against challenge infection of vacci-
nated animals. In addition, levels of each predictor associated with
maximum levels of protection were estimated.
MATERIALS AND METHODS
SYSTEMATIC REVIEW
An electronic literature search was performed using Science Cita-
tion Index Expanded, Conference Proceedings Citation Index
and BIOSIS Citation Index, all of which were provided through
Web of Knowledge1. Alongside these, EMBASE2, OVID MEDI-
CINE3, and CAB abstracts, were searched simultaneously though
OvidSP4. Reference lists of all articles identified by the elec-
tronic search were searched manually for additional relevant
reference. In addition, ProQuest Dissertations and Thesis Full
Text5 was searched as a source of pre-published and gray lit-
erature. The search terms were chosen to be as inclusive as
possible and were “cercaria*” AND (“irradiat*” OR “attenuat*”)
AND (“vaccin*OR schistosom*”). Also, we searched by “Atten-
uate*” AND “schistosome*” AND “vaccin*.” This search was
completed in July 2013. After duplicated articles were removed
a total of 1,013 articles were identified. Titles and abstracts
were screened by at least two independent reviewers to exclude
those that were not relevant to an attenuated schistosome vac-
cine animal model. Full texts of potentially relevant articles were
reviewed by two independent reviewers for further selection.
Non-English articles were included, and several Chinese and Ger-
man articles were identified and translated into English by a
native Chinese speaker and German speaker, respectively, for the
analysis.
A study was considered eligible if it met all of the follow-
ing inclusion criteria: (1) vaccination with attenuated cercariae;
(2) use of ionizing radiation for attenuation; (3) use of percuta-
neous immunization and challenge (i.e., the natural transmission
route for schistosome infection); (4) challenge infection using nor-
mal (non-attenuated) cercariae; (5) worm burden measured after
the challenge infection via perfusion; (6) outcome (fraction of
protection) reported or could be calculated. In this study, frac-
tion of protection means the proportion of reduction in worm
burden in vaccinated mice compared to that of control mice
group. For articles, which reported worm count after challenge
infection, the following equation was used to calculate the out-
come: fraction of protection= [(average number of worms per
mouse retrieved from control group− average number of worms
per mouse retrieved from vaccinated group)/average number of
worms per mouse retrieved from control group]. In the case of
articles, which failed to report worm counts (allowing calculation
1http://www.webofknowledge.com
2http://www.elsevier.com
3http://www.ovid.com
4http://ovidsp.tx.ovid.com
5http://www.proquest.com
of this quantity), only those that stated that they used the same
equation as above were included.
Studies were excluded if they met any of the following exclu-
sion criteria: (1) immunizing attenuated cercariae developed to
adulthood; (2) hosts were transgenic or genetically engineered; (3)
hosts had an in vivo depletion of immune cells; (4) attenuated cer-
cariae were prepared by any means other than ionizing irradiation;
(5) a non-cercarial vaccine was used (e.g., adult worm, schistoso-
mula, subunit); (6) an artificial infection was conducted prior to
vaccination; or (7) hosts were treated with anthelmintic drugs.
Articles often reported results from multiple separate experi-
ments such as use of different doses of attenuated parasite. In these
cases, results from each experiment were recorded as an observa-
tion. A total of 755 observations from 105 articles (articles are
listed in Supplementary Material) meeting searching criteria and
also using mouse as a host and S. mansoni for vaccination and
challenge infection. Although the mouse is not a natural host for
schistosome infection, it is the most commonly used animal for
attenuated schistosome parasite vaccine animal model. A list of
potential predictors (given in Table 1) was drawn up and these
quantities were extracted from each article. These potential pre-
dictors have been suggested their importance by review articles and
also their quantities been reported by many experimental studies
(26). When an article reported a dose range rather than an exact
dose the mid-value was used for the analysis.
STATISTICAL ANALYSIS
Random effects meta-regression
Random effects meta-regression was used to identify the influen-
tial predictors and effect of dose on protection. Multiple obser-
vations (1–56) were recorded from single articles and therefore
article was included as a random effect in the models. The mod-
els were built using a backwards stepwise procedure with eight
potential predictors (listed in Table 1). The effect of the number
of immunizing parasites was explored in two ways in the two sep-
arate models: as an average number of immunizing parasites per
dose or as a total number of immunizing parasites. Correlations
between variables were examined visually by scatter plot graphs
for all possible predictor combinations (data not shown). Then,
Table 1 | Possible predictors investigated and their units/codes.
Variable name Units/code
Number of immunizing parasites (total and number
per dose)
Number of parasites
log10 transformed
Number of challenge parasites Number of parasites
log10 transformed
Number of immunizations Count
Irradiation dose Krad
Host age Weeks
Host sex Male, female, mixed
Time between the last immunization and challenge Days
Time between challenge and perfusion Days
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all the possible combinations of two-way interactions of potential
predictors were examined using a random effects meta-regression
model with two-way interactions. The outcome variable (fraction
of protection) was transformed as−ln(1− fraction of protection)
to reduce the skewness of residuals (27). Although using confi-
dence intervals and SE is the most common weighting method for
meta-regression (28), many studies in our dataset failed to report
either confidence intervals or SD and there were no comparable
studies, which enabled us to justify imputing them. Two kinds of
information were available on the size of the studies: the num-
ber of control animals and the number of vaccinated animals. The
majority of studies used similar numbers of control and vaccinated
animals; however, there were several articles, which used a higher
number of vaccinated animals than control animals. To account
for the impact of these unbalanced studies, the number of control
animals was used as the more conservative weighting option.
Missing values and outliers
Several outliers were excluded from the analysis. They were six
observations with animals kept longer than 300 days or <7 days
after the last immunization and four observations that used more
than 10,000 cercariae for immunization. After excluding outliers
745 observations were kept for further selection.
When the numbers of control animals were not reported in an
article and only the numbers of vaccinated animals were given,
numbers of control animals were then imputed by a linear regres-
sion imputation method between numbers of vaccinated and
control animals for all studies (29). When the observation was
missing for both the number of control animals and vaccinated
animals (4 observations from 4 articles), the average number of
control animals of the remaining data set was used for imputation,
which was 10 control animals. Out of 745 observations, 725 obser-
vations from 100 articles reported all predictors and were used for
the analysis.
Statistical software
Papers identified by systematic review were recorded by Thom-
son Reuters EndNote and the extracted data were entered on
a Microsoft Excel 2010 spread sheet for further analysis. IBM
SPSS Statistics Version 19.0 and Minitab. Inc., MINITAB 16 were
used for statistical analysis. GraphPad Software GraphPad Prism
version 6.03 was used for graphical expression.
RESULTS
Among eight potential predictors (Table 1), three predictors
were found to have statistically significant effects (P < 0.05) on
the outcome value −ln(1− fraction of protection) following the
backwards stepwise selection: the log10 transformed total num-
ber of immunizing parasites (P < 0.001), the irradiation dose
(P < 0.001), and the time between the last immunization and chal-
lenge (P = 0.04) (Table 2). The reported ranges of each predictor
were the total number of immunizing parasites (50–5,000 cer-
cariae), the irradiation dose (3–160 krad), and the time between
the last immunization and challenge (7–230 days). All identified
predictors were significant (P < 0.05) in the model no matter with
or without outliers in the model. The number of immunizing par-
asites was significant in the model regardless of the version of this
Table 2 | Results from random effects meta-regression models.
Predictors Coefficient SE P -value
Number of immunizing parasites
per dose (log10 transformed)
0.4338 0.0661 <0.001
Irradiation dose −0.0047 0.0008 0.04
Time between the last
immunization and challenge
−0.0015 0.0007 <0.001
Positive coefficients indicate the predictor’s positive dose effect on fraction of
protection whereas negative coefficients indicate predictor’s negative influence
on fraction of protection.
variable used, i.e., the average number of immunizing parasites per
dose or total number of immunizing parasites. In both cases, the
models were initially considered with the number of immuniza-
tions. When the total number of immunizing parasites was used
as a predictor, the number of immunizations was not significant.
Therefore, for the final model, the total number of immunizing
parasite was used as a predictor with number of immunizations
excluded from the model.
The interaction between log10 transformed total number of
immunizing parasites and the time between the last immunization
and challenge was statistically significant (P = 0.04). However, this
interaction was excluded from the final model for the following
reasons: (1) the model with the interaction showed biologically
implausible fitted values of fraction of protection for some predic-
tors, (2) the model with/without interaction showed similar fitted
values for the fraction of protection around the most frequent
values of predictors.
Fitted graphs for each predictor are shown in Figure 1 with
the outcome variable back-transformed to fraction of protection.
Fitted graphs for each predictor were generated by fixing other pre-
dictor values at their modes: 500 immunizing parasites, 28 days
for the time between the last immunization and challenge, and
20 krad for irradiation dose (solid line in Figure 1). The fitted
graph of total number of immunizing parasites and fraction of
protection showed the lowest level of predicted protection was
41% with 50 cercariae, which increased up to 75% with 5,000
cercariae (solid line in Figure 1A). Similarly, the minimum level
of protection predicted for 160 krad irradiation was 26% protec-
tion, which increased to 65% with 3 krad irradiation (solid line in
Figure 1B). The estimated level of protection 7 days after the last
immunization was 63%, which reduced to 49% by 230 days after
the last immunization (solid line in Figure 1C). Fitted graphs
showed that the total number of immunizing parasites had a posi-
tive impact on the fraction of protection whereas irradiation dose
and the time between the last immunization and challenge had
negative impacts (Figure 1). Besides this, to estimate the highest
protection, fitted graphs for each predictor were generated with
other predictor values at their optimal level: 5,000 immunizing
parasites, 7 days for the time between the last immunization and
challenge, and 3 krad for irradiation dose (dashed line in Figure 1).
The models suggested that highest achievable protection was 78%
at 7 days after the last immunization, with the mouse immunized
with 5,000 cercariae, which were attenuated with 3 krad (dashed
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FIGURE 1 | Fitted graphs for identified predictors from a random
effects meta-regression model. Identified predictors effects on fraction of
protection in mouse model: (A) the number of immunizing cercariae over
the range 50–5,000 cercariae, (B) the irradiation dose over the range
3–160 krad, (C) the time between the last immunization and challenge over
the range 7–230 days. Data points indicate reported fraction of protection
for each observation. Negative fractions indicate that vaccination was
associated with increase of schistosome worm burden. Lines are fitted
graphs generated from random effects meta-regression model (see text).
Dashed lines in the graphs show the highest level of protection over range
that could be achieved.
line in Figure 1). This 78% protection will decrease over time but
would stay as high as 70% by 230 days after the last immunization
(dashed line in Figure 1C).
DISCUSSION
Irradiated S. mansoni cercariae vaccines have been tested exper-
imentally against schistosome infection for decades, with impor-
tant insights obtained from the individual experiments (25).
Although the translation of the irradiated parasites vaccine in
humans has not been pursued for schistosomiasis, a precedent
for this type of approach for human vaccination has been set by
malaria vaccine, which uses live attenuated sporozoites (Sanaria®
PfSPZ Vaccine) and has now completed phase 1/2a clinical trial
(30). This study represents a meta-analysis of the experimental
irradiated cercariae vaccine studies to identify robust variables that
affect the levels of protection to inform human vaccine research
and development.
The random effect meta-regression models identified three pre-
dictors of a reduction in worm burden: these were the total number
of irradiated cercariae per immunization, the time between the
last immunization and challenge, and the irradiation dose for par-
asite attenuation. We identified a positive correlation between the
number of irradiated cercariae per immunization and the level
of protection within the range of 50–5,000 cercariae used in the
original studies. The models suggested that the optimally prepared
irradiated cercariae vaccine could achieve a protection as high as
78% against challenge infection. As fitted graphs have shown, this
is predicted for a single vaccination with 5,000 cercariae attenu-
ated with 3 krad irradiation. This protection declines over time,
but remains high for at least 8 months after the last immunization.
Approximately 70% protection against challenge infection could
be achieved after 8 months.
The number of immunizing cercariae represents the antigen
dose, our results show a positive dose dependency of schistosome
attenuated vaccine for higher protection. Studies of live attenuated
vaccine for malaria infection also reported a similar positive cor-
relation between the dose of immunizing parasites and the level of
protection against future infection. Recently, as part of the phase
1 clinical trial of the human malaria vaccine using live attenu-
ated sporozoites (Sanaria® PfSPZ Vaccine), a dose-escalation trial
was conducted using 7,500–135,000 irradiated Plasmodium fal-
ciparum sporozoites per immunization. The participants group
that received the highest dose per immunization achieved the
highest levels of protection against challenge infection (31–33).
Although the adequate number of immunizing schistosome par-
asites are needed to protect baboon hosts has not been well
quantified yet, experimental studies have been conducted with up
to 45,000 schistosome parasites and reported positive protections
(34–36). These reports suggest that a large number of attenu-
ated cercariae would be required for vaccination in humans. The
intermediate host snails have been reported to shed a large num-
ber of cercariae that is approximately 3,600–6,000 cercariae per
snail over the first 50 days of shedding (37). Schistosome infected
snails and cercariae are commercially available from organiza-
tions such as the NIH-NIAID Schistosomiasis Resource Center
(38) and Schistosomiasis Collection at the Museum at National
History Museum, London for laboratory use (39). Clearly pro-
ducing an adequate number of cercariae of a satisfactory quality
to use in vaccinations is still highly challenging (18). Although we
cannot directly translate animal vaccine study results into human
use, their value is in highlighting the nature and development
of vaccine induced protective immunity against schistosomia-
sis. For example, the dynamic relationships between vaccination
dose and level of protection are informative for human stud-
ies, as has been alluded to by drug induced resistance against
re-infection (40, 41). It is also worth mentioning that human
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vaccination trials using infection or irradiated parasite vaccina-
tion have recently been conducted in human P. falciparum studies
(42–44).
The result from the random effects meta-regression model
showed a decrease in the fraction of protection with an increased
time between the last immunization and challenge. This period
between immunization and challenge represents the time to
secondary encounter with the same antigen. When the initial
encounter with the antigen takes place via infection or vaccina-
tion, the number of B and T cell produced against the antigen
increases dramatically (45–48). Only a small fraction of those cells
will survive as antigen-specific memory T and B cells or as long-
lived plasma cells and they will be maintained for a long time
(45–48). The duration of immune memory in humans after the
vaccination is still controversial (49). However, there are several
reports estimates for the length of immune memory after the last
booster vaccination; 15 years for combined hepatitis A and B vac-
cine (50), 22 years for hepatitis B vaccine (51), over 30 years for
poliovirus vaccine (49, 52), and over 60 years for small pox vac-
cine (49, 53). A longitudinal immuno-epidemiological study of
schistosomiasis has been conducted by Butterworth et al., which
reported that the protection induced by chemotherapy can remain
for as long as 21 months after the treatment (54). However, other
studies reported treated participants’ re-infection within 1 year
(12, 55). One of the difficulties in evaluating the length of pro-
tective immunity in humans is that, in contrast to experimental
animals, humans encounter a variety of antigens that could stim-
ulate their immune systems through their daily life. In addition,
people infected and being treated for schistosomiasis normally
live in schistosomiasis endemic areas. Regarding the influence of
schistosome infection on vaccine efficacy, Kariuki et al. have shown
that the protection levels induced by attenuated cercariae vaccina-
tion were high in baboon hosts in a group chronically infected
and then treated after vaccination, as well as in a group that was
infected and previously treated before vaccination (36). In addi-
tion, encounters with infectious cercariae by people in endemic
areas may work as a “natural booster” to stimulate protective
immunity. In our study, the times between the last immunization
and challenge (7–230 days) were relatively short compared with
the life span of humans and schistosome parasites. This reflects
that the average lifespan of a mouse is much shorter than that
of the schistosome parasite (56, 57). The decrease in the frac-
tion of protection over time was captured with our models even
within this relatively short time range. This result would suggest
that boosting vaccines may be necessary for long lasting protection
against schistosomes.
There are several different cercariae attenuation methods as we
described in the introduction. Within these, ionizing radiation
(X-ray and gamma ray) is the most commonly used attenua-
tion method for attenuated schistosome cercariae preparation.
Two relatively high irradiation doses around 20 or 50 krad have
been reported as the optimal doses for parasite attenuation (58,
59) and, in fact, many past studies have applied these irradia-
tion doses. However, our results suggest that a lower irradiation
dose could improve protection. The lower irradiation doses enable
attenuated parasites to live longer in the vaccinated host. After
vaccination, irradiated cercariae have been reported to be present
around the skin exposure site for approximately 4 days and then
gradually moved to the lungs where they transformed from cer-
cariae into lung-stage schistosomula (60). It has been reported
that the immunizing parasite has to reach the lungs and transform
to lung-stage schistosomula to elicit protective immunity against
challenge infection (60, 61), which may not be the case for cer-
cariae attenuated with high doses of ionizing radiation. Several
studies have reported that non-attenuated challenge cercariae in
vaccinated mice slowly move to the lungs and then gradually dis-
appear (61, 62). Several studies report that cercariae exposed to
extremely high irradiation doses will die in the host skin before
they start to migrate inside the host body (60, 63). Mountford et al.
reported that hosts needed to be exposed to both highly irradiated
cercariae, which die in the host skin, and lung-stage schistosome
parasites to elicit protective immunity (64). One of the possible
reasons for the high levels of protection observed when using irra-
diated cercariae vaccine is that hosts are exposed to a wide variety
of antigens, which are expressed by different parasite life stages.
Parasites, which were attenuated with lower irradiation dose, can
survive long enough to express a variety of antigens from differ-
ent life stages (65). However, in practice, allowing parasites to live
longer inside vaccinated people may not be well accepted or ethi-
cally approved. The results of our meta-analysis suggests that for
recombinant vaccine development the combination of antigens,
which are unique to the different schistosome life stages may be
an important factor in achieving a better protection.
CONCLUSION
In this study, we identified three predictors for effective immu-
nization against schistosome infection using attenuated cercariae:
the total number of immunizing parasites, the irradiation dose,
and the time between the last immunization and challenge. The
study results suggested that the optimally prepared irradiated cer-
cariae vaccine could achieve a protection as high as 78% against
challenge infection. Within the reported dose range, the maxi-
mum protection could be achieved with the highest number of
immunizing cercariae (5,000 cercariae) and the lowest irradiation
dose (3 krad). This protection slowly declines but remains high
for at least 8 months after the last immunization. This achievable
protection is much higher than the partial protection reported by
the S. mansoni purified antigens that failed to achieve consistent
protection above 40% in mice (21, 66, 67). Although none of the
radiation attenuated cercariae vaccine studies achieved complete
protection against challenge infection, it is thought that partial
protection induced by immunization can significantly reduce both
schistosome related morbidity and parasite transmission (68, 69).
This meta-analysis shows there is the high potential for an atten-
uated cercarial vaccine, while also providing insights helpful for
schistosome vaccine development more generally.
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